Loading company…
Resthetic Bio develops technologies for cartilage repair and regeneration.
Resthetic Bio develops biologics and scaffold technologies for cartilage repair and regeneration, targeting orthopedic conditions including osteoarthritis and cartilage injuries. Founded in 2017, the company is based in Shanghai, China. It raised CNY 100 million in Pre-Series A funding on April 21, 2026, from Nuoyu Capital and Real Power Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in